Noha Ibrahim
National Cancer Institute, Egypt
Biography:
Dr noha h.ibrahim has her expertise in evaluation and passion in improving the health and wellbeing. Noha Hassan currently works at the Clinical pathology, National Cancer Institute Egypt. Their most recent publication is 'Canc Therapy & Oncol Int J The Potential Prognostic and Diagnostic Role of MiRNAs as Novel Biomarkers for Prostate Cancer'.
Abstract:
Background: The aim of this work is to study the diagnostic efficacy of mRNA expression of survivin and E2F3 between newly diagnosed patients with prostate cancer, patients with benign prostatic hyperplasia (BPH) and healthy normal control, in addition to comparing them with prostate specific antigen (PSA) that is routinely used in patients with prostate cancer. Also, to study their association with some of the clinicopathological findings of prostate cancer.
Methods: This study included 125 participants; seventy-five patients with prostate adenocarcinoma (PC) presented to the outpatient clinic at the National Cancer Institute, Cairo University over a period of 10 consecutive months from December 2017 to September 2018. Twenty-five patients with BPH and twenty-five, apparently healthy, volunteers were included as benign and normal control groups, respectively. There was detection of survivin and E2F3 mRNA on whole blood samples collected on tubes containing EDTA for all patients and control subjects using semi-quantitative real-time PCR.
Results: Survivin mRNA expression, total PSA, free PSA and PSA ratio showed a statistically significant difference among the control, BPH and PC groups (all have P-value <0.001). On the other hand, E2F3 gave no statistical difference (p=0.272). Survivin is highly expressed in PC than BPH and normal groups and considered as risk factor (OR=1.75, p-value=0.011). survivin and E2F3 has no association with clinicopathological factors of prostate cancer.